$HALB "The Street Podcast" Features Halberd's "Gro
Post# of 630
(Total Views: 239)
Posted On: 12/05/2022 8:25:16 AM
$HALB "The Street Podcast" Features Halberd's "Groundbreaking" Cancer Treatment Approach.
https://www.accesswire.com/730015/the-street-...listen-now
CEO William Hartman and CTO Mitchell Felder report successful application of Halberd's patented methodology for Cancer Antigen Eradication Treatment.
JACKSON CENTER, PA / ACCESSWIRE / December 5, 2022 / Halberd Corporation's (OTC-PINK:HALB) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S. Felder, interviewed on "The Street Reports," discuss their groundbreaking accomplishments, successfully eradicating Cancer disease antigens".
Listen here: https://thestreetreports.com/the-street-podca...r-discuss/
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "The control of various cancer antigen levels is an indispensable step in eliminating and preventing cancer. The HALB approach is to control the exact concentration (to the picogram/ml level) of CTLA-4. The goal is to precisely lower CTLA-4 concentration to the exact, perfect level which would allow the cancer to be destroyed by the immune system, yet not cause any deleterious side effects. We have successfully applied this same technique of controlling antigen levels to other diseases with consistent success. So far, we have demonstrated this control in-vitro, and are moving to in-vivo testing in animals, and eventually in humans."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "What differentiates Halberd Corporation's patent protected approach from other applications is our extracorporeal (outside the body) method. We don't inject anything into the patient nor have them ingest drugs. Our process reduces or eliminates the negative side effects of medications. Over 100,000 deaths in the U.S. are the result of drug side-effects1."
https://www.accesswire.com/730015/the-street-...listen-now
CEO William Hartman and CTO Mitchell Felder report successful application of Halberd's patented methodology for Cancer Antigen Eradication Treatment.
JACKSON CENTER, PA / ACCESSWIRE / December 5, 2022 / Halberd Corporation's (OTC-PINK:HALB) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S. Felder, interviewed on "The Street Reports," discuss their groundbreaking accomplishments, successfully eradicating Cancer disease antigens".
Listen here: https://thestreetreports.com/the-street-podca...r-discuss/
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "The control of various cancer antigen levels is an indispensable step in eliminating and preventing cancer. The HALB approach is to control the exact concentration (to the picogram/ml level) of CTLA-4. The goal is to precisely lower CTLA-4 concentration to the exact, perfect level which would allow the cancer to be destroyed by the immune system, yet not cause any deleterious side effects. We have successfully applied this same technique of controlling antigen levels to other diseases with consistent success. So far, we have demonstrated this control in-vitro, and are moving to in-vivo testing in animals, and eventually in humans."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "What differentiates Halberd Corporation's patent protected approach from other applications is our extracorporeal (outside the body) method. We don't inject anything into the patient nor have them ingest drugs. Our process reduces or eliminates the negative side effects of medications. Over 100,000 deaths in the U.S. are the result of drug side-effects1."
(0)
(0)